Neos Therapeutics, Inc.

Life Biosciences Secures First FDA Approval for Human Epigenetic Reprogramming Trial to Reverse Vision Loss

- Life Biosciences, cofounded by Harvard geneticist David Sinclair, received FDA approval for the first human trial testing partial epigenetic reprogramming to restore vision in patients with glaucoma and NAION. - The Phase 1 trial will inject viruses carrying three reprogramming genes directly into patients' eyes, with the treatment controlled by doxycycline antibiotic dosing over two months. - This breakthrough puts the Boston startup ahead of well-funded competitors like Altos Labs and NewLimit in the race to develop age reversal therapies. - The trial represents a milestone in longevity research, marking the first targeted attempt at cellular age reversal in human volunteers.